Poseida Therapeutics

Roche plans to acquire Poseida Therapeutics for $1 billion to advance off-the-shelf CAR-T cell therapies. Tenaya Therapeutics dosed its first patient with TN-401 gene therapy for ARVC. The FDA granted RMAT designation to Intellia's nex-z CRISPR-based therapy for hereditary transthyretin amyloidosis.

Roche acquires Poseida Therapeutics for $1.5BN, highlighting Big Pharma interest in cell therapy for cancer. Arovella Therapeutics (ASX:ALA), also focused on cell therapy for cancer, plans to start its Phase 1 trial in 2025. ALA's strategy includes developing 'off-the-shelf' cell therapies and has an impressive clinical advisory board, including a prominent researcher from Kite Pharma, acquired by Gilead for $11.9BN. ALA aims to achieve a major breakthrough in cancer immunotherapy and potentially be acquired by a major pharmaceutical company.

DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.

Sponsors must prioritize comprehensive support models in clinical research. Shingles can occur in children post-chickenpox. Roche to acquire Poseida Therapeutics for $1.5 billion. Care Access launches health screening in Birmingham. Robert Meister shares a LinkedIn post.

Poseida Therapeutics' P-BCMA-ALLO1, an allogeneic BCMA-directed CAR-T therapy, showed 91% ORR in a phase 1/1b trial for r/r MM, with no graft versus host disease and low CRS risk. Enhanced lymphodepletion improved in vivo expansion and persistence, addressing unmet needs for patients failing other therapies.

Poseida Therapeutics’ P-BCMA-ALLO1, an allogeneic BCMA-directed CAR-T therapy, is being evaluated in a phase 1/1b clinical trial for relapsed/refractory multiple myeloma. The therapy, which does not require leukapheresis or manufacturing wait times, demonstrated a 91% overall response rate and no graft versus host disease in the enhanced lymphodepletion arm, as presented at the 21st International Myeloma Society Annual Meeting.

William Blair analyst Sami Corwin maintains a Buy rating on PTC Therapeutics (PTCT) stock due to the FDA approval of Kebilidi, a groundbreaking gene therapy for AADC deficiency, and the company's proactive commercial launch preparations. Corwin's rating is further supported by the priority review voucher and promising clinical trial results.

Beam Therapeutics acknowledges a patient death in a Phase 1/2 trial for sickle cell disease, attributing it to pre-conditioning, not the base-editing treatment. AstraZeneca, UT, and LIVESTRONG report successful therapeutic genome editing in mouse liver via lipid nanoparticles. Korean researchers find base and prime editors produce fewer large DNA deletions than Cas9 nucleases. YolTech demonstrates effective mRNA delivery to bone marrow cells for blood disorder treatment. Japanese scientists develop a curative strategy for congenital purpura fulminans using engineered APC. US-France team identifies key host factors enhancing rotavirus vaccine production. Allogene Therapeutics shares positive Phase 1 data for renal cell carcinoma treatment. Cellectis presents strategies to enhance CAR T-cell efficacy in solid tumors. Caszyme and Integra Therapeutics enter a licensing agreement for safer gene therapies. Industry updates include financial results and clinical trial progress from various companies. CRISPR genome engineering symposium to feature latest advancements. CRISPR gene editing can integrate mitochondrial DNA into the nuclear genome, but exonucleases can mitigate this. HuidaGene Therapeutics' CRISPR-Cas13 RNA-editing therapy for macular degeneration is accepted by the FDA.

Poseida Therapeutics to present new preclinical data on allogeneic CAR+TCR-T cells rich in TSCM at SITC 2024, with additional patient response profiling from P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 data at ASH 2024.